Recent Advances in Targeted Therapies for Adult Gliomas

The provided text details the evolving landscape of adult glioma treatment, highlighting a significant transition from traditional histology to molecularly-driven diagnostics and targeted therapies. Recent FDA approvals have introduced precision agents such as vorasidenib for IDH-mutant tumors, dabrafenib-trametinib for BRAF-mutated cases, and dordaviprone for specific midline gliomas. While these advancements offer tangible clinical benefits and the potential to delay toxic chemoradiation, the sources note that these targets are present in only a minority of patients and are not yet curative. Beyond established treatments, the text evaluates investigational strategies focusing on DNA repair mechanisms, metabolic vulnerabilities like MTAP deletion, and advanced delivery methods such as CAR T-cell therapy. Despite this progress, researchers face persistent obstacles including the blood-brain barrier, tumor heterogeneity, and the rapid development of therapeutic resistance. Overall, the sources summarize how integrated molecular profiling is currently redefining the classification and management of primary brain tumors.